We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Protocol for Radiofrequency Ablation of Pulmonary Neoplasms

This study has been terminated.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00232128
First Posted: October 4, 2005
Last Update Posted: January 12, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Oncology Specialties, Alabama
  Purpose
This research trial involves the development of a new treatment for lung tumors. It is for patients whose tumor cannot be surgically removed, have refused surgery, or the tumor has not responded well to other forms of treatment. This treatment uses a needle probe to deliver energy into the lung tumor. This probe is placed utilizing a CT scan image. The energy heats the tumor causing tumor cell death.

Condition Intervention
Pulmonary Neoplasms Procedure: Radiofrequency Ablation of pulmonary neoplasms

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Protocol for Radiofrequency Ablation of Pulmonary Neoplasms

Resource links provided by NLM:


Further study details as provided by Oncology Specialties, Alabama:

Study Start Date: June 2003
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   19 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria: The patients enrolled in this study should be judged to have sufficient survival to benefit from control of local disease and include at least one of the following:

  1. unresectable primary or metastatic lung tumors
  2. may benefit from multiple modalities of therapy
  3. chemotherapeutic or radiation oncologic options have been exhausted

Exclusion Criteria:

1. co-existing morbidities that preclude the use of surgery

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00232128


Locations
United States, Alabama
Comprehensive Cancer Institute
Huntsville, Alabama, United States, 35801
Sponsors and Collaborators
Oncology Specialties, Alabama
Investigators
Principal Investigator: Marshall T. Schreeder, M.D. Comprehensive Cancer Institute
  More Information

ClinicalTrials.gov Identifier: NCT00232128     History of Changes
Other Study ID Numbers: CCI LUN 02
First Submitted: October 3, 2005
First Posted: October 4, 2005
Last Update Posted: January 12, 2007
Last Verified: May 2006

Additional relevant MeSH terms:
Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases